Literature DB >> 22895264

Intracholecystic papillary-tubular neoplasms (ICPN) of the gallbladder (neoplastic polyps, adenomas, and papillary neoplasms that are ≥1.0 cm): clinicopathologic and immunohistochemical analysis of 123 cases.

Volkan Adsay1, Kee-Taek Jang, Juan Carlos Roa, Nevra Dursun, Nobuyuki Ohike, Pelin Bagci, Olca Basturk, Sudeshna Bandyopadhyay, Jeanette D Cheng, Juan M Sarmiento, Oscar Tapia Escalona, Michael Goodman, So Yeon Kong, Paul Terry.   

Abstract

The literature on the clinicopathologic characteristics of tumoral intraepithelial neoplasms (neoplastic polyps) of the gallbladder (GB) is fairly limited, due in part to the variability in definition and terminology. Most reported adenomas (pyloric gland type and others) were microscopic and thus regarded as clinically inconsequential, whereas papillary in situ carcinomas have been largely considered a type of invasive adenocarcinoma under the heading of "papillary adenocarcinomas." In this study, 123 GB cases that have a well-defined exophytic preinvasive neoplasm measuring ≥1 cm were analyzed. The patients were predominantly female (F/M=2:1) with a mean age of 61 y and a median tumor size of 2.2 cm. Half of the patients presented with pain, and in the other half the neoplasm was detected incidentally. Other neoplasms, most being gastrointestinal tract malignancies, were present in 22% of cases. Gallstones were identified in only 20% of cases. Radiologically, almost half were diagnosed as "cancer," roughly half with polypoid tumor, and in 10% the lesion was missed. Pathologic findings: (1) The predominant configuration was papillary in 43%, tubulopapillary in 31%, tubular in 26%. (2) Each case was assigned a final lineage type on the basis of the predominant pattern (>75% of the lesion) on morphology, and supported with specific immunohistochemical cell lineage markers. The predominant cell lineage could be identified as biliary in 50% (66% of which were MUC1), gastric foveolar in 16% (all were MUC5AC), gastric pyloric in 20% (92% MUC6), intestinal in 8% (100% CK20; 75% CDX2; 50%, MUC2), and oncocytic in 6% (17% HepPar and 17% MUC6); however, 90% of cases had some amount of secondary or unclassifiable pattern and hybrid immunophenotypes. (3) Of the cases that would have qualified as "pyloric gland adenoma," 21/24 (88%) had at least focal high-grade dysplasia and 18% had associated invasive carcinoma. Conversely, 8 of 47 "papillary adenocarcinoma"-type cases displayed some foci of low-grade dysplasia, and 15/47 (32%) had no identifiable invasion. (4) Overall, 55% of the cases had an associated invasive carcinoma (pancreatobiliary type, 58; others, 10). Factors associated significantly with invasion were the extent of high-grade dysplasia, cell type (biliary or foveolar), and papilla formation. Among systematically analyzed invasive carcinomas, tumoral intraepithelial neoplasia was detected in 6.4% (39/606). (5) The 3-year actuarial survival was 90% for cases without invasion and 60% for those associated with invasion. In contrast, those associated with invasion had a far better clinical outcome compared with pancreatobiliary-type GB carcinomas (3-yr survival, 27%), and this survival advantage persisted even with stage-matched comparison. Death occurred in long-term follow-up even in a few noninvasive cases (4/55; median 73.5 mo) emphasizing the importance of long-term follow-up. In conclusion, tumoral preinvasive neoplasms (≥1 cm) in the GB are analogous to their pancreatic and biliary counterparts (biliary intraductal papillary neoplasms, pancreatic intraductal papillary mucinous neoplasms, and intraductal tubulopapillary neoplasms). They show variable cellular lineages, a spectrum of dysplasia, and a mixture of papillary or tubular growth patterns, often with significant overlap, warranting their classification under 1 unified parallel category, intracholecystic papillary-tubular neoplasm. Intracholecystic papillary-tubular neoplasms are relatively indolent neoplasia with significantly better prognosis compared with pancreatobiliary-type GB carcinomas. In contrast, even seemingly innocuous examples such as those referred to as "pyloric gland adenomas" can progress to carcinoma and be associated with invasion and fatal outcome.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22895264     DOI: 10.1097/PAS.0b013e318262787c

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  45 in total

1.  Clinical and pathological features of intraductal papillary neoplasm of the biliary tract and gallbladder.

Authors:  Sean Bennett; E Celia Marginean; Melanie Paquin-Gobeil; Jason Wasserman; Joel Weaver; Richard Mimeault; Fady K Balaa; Guillaume Martel
Journal:  HPB (Oxford)       Date:  2015-09       Impact factor: 3.647

2.  Intracholecystic papillary-tubular neoplasm of the gallbladder originating in the cystic duct with extensive intraepithelial progress in the common bile duct.

Authors:  Yuki Fujii; Yutaka Noda; Shinsuke Koshita; Yoshihide Kanno; Takahisa Ogawa; Hiroaki Kusunose; Kaori Masu; Toshitaka Sakai; Keisuke Yonamine; Yujiro Kawakami; Toji Murabayashi; Fumisato Kozakai; Takashi Sawai; Toru Furukawa; Kei Ito
Journal:  Clin J Gastroenterol       Date:  2018-11-30

3.  Gallbladder Mixed Neuroendocrine-Non-neuroendocrine Neoplasm (MiNEN) Arising in Intracholecystic Papillary Neoplasm: Clinicopathologic and Molecular Analysis of a Case and Review of the Literature.

Authors:  Amedeo Sciarra; Edoardo Missiaglia; Mounir Trimech; Emmanuel Melloul; Jean-Philippe Brouland; Christine Sempoux; Stefano La Rosa
Journal:  Endocr Pathol       Date:  2020-03       Impact factor: 3.943

4.  Organ-specific concept and controversy for premalignant lesions and carcinogenesis of gallbladder cancer.

Authors:  Keita Kai
Journal:  Hepatobiliary Surg Nutr       Date:  2016-02       Impact factor: 7.293

5.  Gallbladder cancer: expert consensus statement.

Authors:  Thomas A Aloia; Nicolas Járufe; Milind Javle; Shishir K Maithel; Juan C Roa; Volkan Adsay; Felipe J F Coimbra; William R Jarnagin
Journal:  HPB (Oxford)       Date:  2015-08       Impact factor: 3.647

6.  Tubulopapillary adenoma of the gallbladder accompanied by bile duct tumor thrombus.

Authors:  Kentaroh Yamamoto; Fumio Yamamoto; Atsuhiro Maeda; Hirotsune Igimi; Mami Yamamoto; Ryosuke Yamaguchi; Yuichi Yamashita
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

7.  Pathologic Evaluation and Reporting of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Other Tumoral Intraepithelial Neoplasms of Pancreatobiliary Tract: Recommendations of Verona Consensus Meeting.

Authors:  Volkan Adsay; Mari Mino-Kenudson; Toru Furukawa; Olca Basturk; Giuseppe Zamboni; Giovanni Marchegiani; Claudio Bassi; Roberto Salvia; Giuseppe Malleo; Salvatore Paiella; Christopher L Wolfgang; Hanno Matthaei; G Johan Offerhaus; Mustapha Adham; Marco J Bruno; Michelle D Reid; Alyssa Krasinskas; Günter Klöppel; Nobuyuki Ohike; Takuma Tajiri; Kee-Taek Jang; Juan Carlos Roa; Peter Allen; Carlos Fernández-del Castillo; Jin-Young Jang; David S Klimstra; Ralph H Hruban
Journal:  Ann Surg       Date:  2016-01       Impact factor: 12.969

Review 8.  Pathological features and diagnosis of intraductal papillary mucinous neoplasm of the pancreas.

Authors:  Víctor M Castellano-Megías; Carolina Ibarrola-de Andrés; Guadalupe López-Alonso; Francisco Colina-Ruizdelgado
Journal:  World J Gastrointest Oncol       Date:  2014-09-15

9.  Pathological characteristics of intraductal polypoid neoplasms of bile ducts in Thailand.

Authors:  Takeo Nitta; Yasuni Nakanuma; Yasunori Sato; Satoshi Hirano; Chawalit Pairojkul
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

10.  Intracholecystic tubular non-mucinous neoplasm (ICTN) of the gallbladder: a clinicopathologically distinct, invasion-resistant entity.

Authors:  Burcin Pehlivanoglu; Serdar Balci; Olca Basturk; Pelin Bagci; Ipek Erbarut Seven; Bahar Memis; Nevra Dursun; Kee-Taek Jang; Burcu Saka; Nobuyuki Ohike; Takuma Tajiri; Juan Carlos Roa; Juan M Sarmiento; Michelle D Reid; Volkan Adsay
Journal:  Virchows Arch       Date:  2020-07-20       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.